Hongyuan Pharmaceutical's first-half revenue up 52% year on year, lithium hexafluorophosphate sees higher volumes and prices

Earnings
โดย 证券时报·CN·Read original
Summary · why it matters

Hongyuan Pharmaceutical disclosed on the evening of August 27 that its operating revenue for the first half of 2026 was 1.342 billion yuan, up 52% year on year, with net profit attributable to the parent company of 156 million yuan. The company said the revenue increase was mainly driven by higher volumes and prices of lithium hexafluorophosphate during the period. By product, lithium battery materials revenue reached 609 million yuan, up 154.9% year on year, while active pharmaceutical ingredients and pharmaceutical intermediates revenue was 496 million yuan, up 5.83%. According to ICC Xinchen Information, global electrolyte production in the first half of 2026 totaled 1.48 million tonnes, up 47.2% year on year, with domestic production accounting for more than 95% of the global total. Lithium hexafluorophosphate production in the first half was 172,000 tonnes, up 43% year on year, and the top five companies in the industry held a combined market share of 69%. Hongyuan Pharmaceutical is currently advancing its third-generation proprietary lithium hexafluorophosphate technology, and its jointly developed technology with Wuhan University for preparing lithium hexafluorophosphate via a rheological phase reaction method has reached an internationally advanced level. The company also revealed that its expansion project for 6,000 tonnes per year of high-purity crystalline lithium hexafluorophosphate is in the trial production stage, and it plans to build a 40,000-tonne-per-year high-purity crystalline lithium hexafluorophosphate production facility in phases in Wuxue.

Impact on stocks 1

Others▲ · 1 stocks

Theme Impact 1

Related news

3impact 4

US, Denmark and Greenland Reach New Security Agreement, Replacing 1951 Pact

The United States has reached an agreement with Greenland and Denmark that will open the way for the US to permanently expand its military and security role on the island of Greenland, while blocking the influence of adversary nations. The three parties are expected to sign jointly during the United Nations General Assembly in New York next week, and the new agreement will replace the 1951 Greenland Defense Agreement. The US State Department stated that the agreement will prohibit countries that are not members of the North Atlantic Treaty Organization, or NATO, from establishing bases or stationing troops in Greenland, and will also bar non-allied countries from investing in mining and critical minerals. These conditions appear aimed at blocking China or Russia from accessing resources or establishing military footholds in Greenland. President Donald Trump posted a message stressing that the United States will be able to do everything necessary to ensure stability and protect the security of Greenland, as well as that of the United States, and confirmed that this is not a transfer of sovereignty or a cession of territory to the US. Meanwhile, Mette Frederiksen, the Prime Minister of Denmark, and Jens-Frederik Nielsen, the Prime Minister of Greenland, confirmed the agreement through a joint statement, with Frederiksen stating that the agreement will help strengthen security in the Arctic and North Atlantic region, while affirming the sovereignty and territorial integrity of the Kingdom of Denmark, as well as the right of Greenlanders to determine their own future.
Defense & Geopolitical Fragmentation ▲Critical Materials & Supply Chain ▼
Politico·2hRead more →
▼

Albemarle Fair Value Cut 7.8% to US$172.56 as Analysts Reset Lithium Assumptions

Albemarle's fair value estimate has been revised down from US$187.16 to US$172.56, a reduction of about 7.8%, as analysts reset their lithium assumptions. The revision reflects updated modeling assumptions, with revenue growth revised from 7.91% to 5.15%, the net profit margin assumption shifted from 34.27% to 35.74%, the future P/E multiple changed from 11.57x to 10.30x, and the discount rate adjusted from 7.41% to 7.50%. Wall Street targets moved broadly lower: Truist cut its target to US$225 from US$245, Scotiabank trimmed its target to US$190 from US$200 while maintaining an Outperform view, RBC Capital reduced its target to US$166 from US$257 while keeping an Outperform rating, and BofA moved its target to US$155 from US$225. On the bearish side, Morgan Stanley cut its target to US$161 from US$189, Mizuho lowered its target to US$185 from US$205 with a Neutral stance, and JPMorgan reduced its target to US$140 from US$160 while maintaining a Neutral rating after updating its model following the Q2 report.
ALB ▼
Critical Materials & Supply Chain ▼
Simply Wall St·14hRead more →

Albemarle Shares Fall 14.3% as Analysts Cut Earnings Estimates

Albemarle has drawn heightened investor attention after its shares returned -14.3% over the past month, compared with a -1.3% change for the Zacks S&P 500 composite and a 6.3% loss for the Zacks Chemical - Diversified industry. For the current quarter, the company is expected to post earnings of $2.55 per share, a change of +1442.1% from the year-ago quarter, though the Zacks Consensus Estimate has fallen 15.9% over the last 30 days. For the current fiscal year, the consensus earnings estimate of $11.39 points to a change of +1541.8% from the prior year and has declined 4.4% over the past month, while the next fiscal year's estimate of $11.07 indicates a -2.8% change and has slipped 3.9%. The consensus sales estimate of $1.52 billion for the current quarter points to a year-over-year change of +16.1%, with $6.1 billion and $6.35 billion expected for the current and next fiscal years. Albemarle reported revenues of $1.74 billion in the last reported quarter, up 31.1% year over year, with EPS of $3.75 versus $0.11 a year ago, and carries a Zacks Rank #3 (Hold) and a Zacks Value Style Score of B.
ALB ▼
Critical Materials & Supply Chain
Zacks Investment Research·19hRead more →
© 2026 MarketDXNews